RTI-126

RTI-126 is a psychoactive drug and research chemical that was first developed in the 1990s by the Research Triangle Institute (RTI). It is part of a series of compounds known as the RTI compounds, which were created in an attempt to develop a substance that could be used as a cocaine substitute. RTI-126 is a dopamine reuptake inhibitor, meaning it increases the levels of dopamine in the brain by blocking its reuptake into neurons.

Chemistry

RTI-126 is a tropane derivative, which is a class of compounds that includes many naturally occurring alkaloids. It is structurally similar to cocaine, but with a different substitution pattern on the tropane ring. The compound is also known as 3β-(4-chlorophenyl)-2β-[3-(4'-methylphenyl)isoxazol-5-yl]tropane or RTI-4229-126.

Pharmacology

As a dopamine reuptake inhibitor, RTI-126 increases the levels of dopamine in the brain. Dopamine is a neurotransmitter that plays a key role in reward, motivation, and motor control. By blocking the reuptake of dopamine, RTI-126 can produce effects similar to those of cocaine, including increased energy, euphoria, and increased alertness.

However, unlike cocaine, RTI-126 does not have a significant effect on the reuptake of norepinephrine or serotonin, which may result in a different side effect profile. The exact effects of RTI-126 in humans are not well-studied, as the compound is primarily used as a research chemical.

Legal Status

RTI-126 is not currently controlled under the United Nations Convention on Psychotropic Substances, but it may be considered illegal in some countries under analogue laws. In the United States, RTI-126 is not specifically listed as a controlled substance, but it could potentially be considered a controlled substance analogue.

See Also

• RTI-31
• RTI-55
• RTI-121
• RTI-352
• RTI-371

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia